In February, US-based Mylan Inc through its Indian subsidiary Mylan Laboratories Ltd (MLL) had signed a definitive agreement to acquire certain female health care businesses from Famy Care Ltd, a speciality women's health care company with global leadership in generic oral contraceptive products (OCPs) for a total consideration of USD 800 million.